04757nam 2201285z- 450 991055779480332120210501(CKB)5400000000045439(oapen)https://directory.doabooks.org/handle/20.500.12854/68373(oapen)doab68373(EXLCZ)99540000000004543920202105d2021 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierNew Prognostic and Predictive Markers in Cancer ProgressionBasel, SwitzerlandMDPI - Multidisciplinary Digital Publishing Institute20211 online resource (294 p.)3-03943-977-4 3-03943-978-2 Biomarkers are of critical medical importance for oncologists, allowing them to predict and detect disease and to determine the best course of action for cancer patient care. Prognostic markers are used to evaluate a patient's outcome and cancer recurrence probability after initial interventions such as surgery or drug treatments and, hence, to select follow-up and further treatment strategies. On the other hand, predictive markers are increasingly being used to evaluate the probability of benefit from clinical intervention(s), driving personalized medicine. Evolving technologies and the increasing availability of "multiomics" data are leading to the selection of numerous potential biomarkers, based on DNA, RNA, miRNA, protein, and metabolic alterations within cancer cells or tumor microenvironment, that may be combined with clinical and pathological data to greatly improve the prediction of both cancer progression and therapeutic treatment responses. However, in recent years, few biomarkers have progressed from discovery to become validated tools to be used in clinical practice. This Special Issue comprises eight review articles and five original studies on novel potential prognostic and predictive markers for different cancer types.Medicine and NursingbicsscacetyltransferaseAKTantigen processing machinery (APM) moleculesARbiomarkerbiomarkersbladder cancerbloodBRCA1/2breast cancercancercancer immunotherapycancer prognosiscarcinogenesiscardioncologycardiotoxicitycastration-resistant prostate cancer (CRPC)CD8+ T effector cellschemo-/radio resistanceCSCCTCscytokinesEMTeribulingenetic syndromesgenomic mutationshead and neck cancerhead and neck neoplasmshead and neck tumorsHRRHUB nodeshuman leukocyte antigen (HLA)hyperglycemiaimmune checkpoint inhibitorK-RAS oncogenelaryngeal cancerlifestyle habitmajor histocompatibility complex (MHC)MAPKmelanomamelanoma resistance to MAPK/MEK inhibitorsmetabolomicsmetastasismicroRNAmiRNAMSI2mTORmusashi 2mutationsN-cadherinn/aNAA10new metastasisnivolumaboncogene dependencyoral cancerOSCCpancreatic cancerparagangliomaPDL1pheochromocytomaPI3KPI3KCApredictionprognosisprostate cancerPTENresistance to immune checkpoint inhibitorsselenoproteinstargeted therapiestherapeutic resistancetherapeutic targetTILsTNBCtranscriptomicstumor predispositionWNTMedicine and NursingCostantini Susanedt1324162Budillon AlfredoedtCostantini SusanothBudillon AlfredoothBOOK9910557794803321New Prognostic and Predictive Markers in Cancer Progression3035971UNINA